Prostate Cancer - Results from #180

Optimal assessment of quality of life for patients with prostate cancer. December 21, 2022

The Changing Landscape of Systemic Therapy in the Treatment of Synchronous Metastatic Hormone-sensitive Prostate Cancer. December 21, 2022

Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial. December 21, 2022

Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma December 20, 2022

Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome. December 20, 2022

Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy. December 20, 2022

Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting. December 20, 2022

A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance. December 20, 2022

Undergoing radical treatment for prostate cancer and its impact on wellbeing: A qualitative study exploring men's experiences. December 20, 2022

Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer. December 20, 2022

Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database. December 19, 2022

Consensus Quality Measures and Dose Constraints for Prostate Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel. December 19, 2022

Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy. December 19, 2022

Chromogranin A: a useful biomarker in castration-resistant prostate cancer. December 19, 2022

Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. December 19, 2022

Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot intervention. December 19, 2022

Salvage irreversible electroporation for radio recurrent prostate cancer - The prospective FIRE trial. December 16, 2022

Predictive factors for tolerance to taxane based chemotherapy in older adults affected by metastatic prostate cancer (ANCHISES-NCT05471427): A prospective observational trial including patients with metastatic hormone sensitive and castrate resistant pros December 16, 2022

What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer? December 16, 2022

Detection of prostate cancer bone metastases with fast whole-body 99mTc-HMDP SPECT/CT using a general-purpose CZT system. December 16, 2022

Page 10 of 1276

email news signup